A comparative study of risk factors and prognostic features between symptomatic and screen detected breast cancer

被引:14
作者
Burke, J. P. [2 ]
Power, C. [2 ]
Gorey, T. F. [1 ,2 ]
Flanagan, F. [1 ,3 ]
Kerin, M. J. [1 ]
Kell, M. R. [1 ,2 ]
机构
[1] Mater Misericordiae Univ Hosp, Eccles Breast Screening, Dublin 7, Ireland
[2] Mater Misericordiae Univ Hosp, Dept Surg, Dublin 7, Ireland
[3] Mater Misericordiae Univ Hosp, Dept Radiol, Dublin 7, Ireland
来源
EJSO | 2008年 / 34卷 / 02期
关键词
breast; neoplasm; screening mammography; prognosis; risk factors; comparative study;
D O I
10.1016/j.ejso.2007.03.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Aims: To compare prognostic factors in screen detected breast cancer (SDBC) and symptomatically presenting breast cancer (SBC). Methods: Data were examined on 100 SDBC and 100 SBC. Multiple clinical patient factors were assessed including histopathological features. Using the Gail model each patient's risk of developing breast cancer was calculated and these data were examined for differences between groups. Results: There was no difference in the mean age of patient presentation or in the risk of breast cancer development between groups (2.2% vs. 2.2%, SDBC vs. SBC, actuarial risk of cancer at 5 years). SDBC patients had a significantly lower grade (1.95 vs. 2.44, SDBC vs. SBC, P < 0.05), a smaller size of tumour (15.4 mm vs. 29.3 mm, SDBC vs. SBC, P < 0.05) and a higher rate of oestrogen (94% vs. 81%, P < 0.05) and progesterone (75% vs. 52%, P < 0.05) receptor positivity. When compared using the Nottingham Prognostic Index, SDBC was associated with a better prognosis (r = -0.444, P < 0.001). Conclusions: Though both groups have similar demographics and risk, SDBC patients appear to have more favourable prognostic features. This has implications for the application of systemic therapy in breast cancer and supports the observation that SDBC is a more indolent form of disease. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:149 / 153
页数:5
相关论文
共 26 条
[1]
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2]
Effect of screening and adjuvant therapy on mortality from breast cancer [J].
Berry, DA ;
Cronin, KA ;
Plevritis, SK ;
Fryback, DG ;
Clarke, L ;
Zelen, M ;
Mandelblatt, JS ;
Yakovlev, AY ;
Habbema, JDF ;
Feuer, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1784-1792
[3]
Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality [J].
Blanks, RG ;
Moss, SM ;
McGahan, CE ;
Quinn, MJ ;
Babb, PJ .
BRITISH MEDICAL JOURNAL, 2000, 321 (7262) :665-669
[4]
Screen-detected vs clinical breast cancer:: the advantage in the relative risk of lymph node metastases decreases with increasing tumour size [J].
Bucchi, L ;
Barchielli, A ;
Ravaioli, A ;
Federico, M ;
De Lisi, V ;
Ferretti, S ;
Paci, E ;
Vettorazzi, M ;
Patriarca, S ;
Frigerio, A ;
Buiatti, E .
BRITISH JOURNAL OF CANCER, 2005, 92 (01) :156-161
[5]
*CANC IAFRO, 2002, IARC HDB CAN PREV
[6]
Hormone replacement therapy in relation to breast cancer [J].
Chen, CL ;
Weiss, NS ;
Newcomb, P ;
Barlow, WN ;
White, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (06) :734-741
[7]
Surgical intervention in screen-detected patients versus symptomatic patients with breast cancer [J].
Dillon, MF ;
Hill, ADK ;
Quinn, CM ;
O'Doherty, A ;
Crown, J ;
Fleming, FJ ;
McDermott, EW ;
O'Higgins, N .
JOURNAL OF MEDICAL SCREENING, 2004, 11 (03) :130-134
[8]
Some current issues in breast cancer screening [J].
Duffy, SW .
JOURNAL OF MEDICAL SCREENING, 2005, 12 (03) :128-133
[9]
PROJECTING INDIVIDUALIZED PROBABILITIES OF DEVELOPING BREAST-CANCER FOR WHITE FEMALES WHO ARE BEING EXAMINED ANNUALLY [J].
GAIL, MH ;
BRINTON, LA ;
BYAR, DP ;
CORLE, DK ;
GREEN, SB ;
SCHAIRER, C ;
MULVIHILL, JJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (24) :1879-1886
[10]
The mammography dilemma: A crisis for evidence-based medicine? [J].
Goodman, SN .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (05) :363-365